**Original Article**

**Let-7g reverses malignant phenotype of osteosarcoma cells by targeting Aurora-B**

Jia Ming Liu¹*, Xin Hua Long¹*, Guo Mei Zhang²*, Yang Zhou¹, Xuan Yin Chen¹, Shan Hu Huang¹, Zhi Li Liu¹, Zhi Hong Zhang¹

¹Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Jiangxi, China; ²Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Jiangxi, China. *Equal contributors and share the first authorship.

Received June 19, 2014; Accepted August 1, 2014; Epub July 15, 2014; Published August 1, 2014

**Abstract:** Accumulating studies revealed that the expression levels of several miRNAs are up or down-regulated in osteosarcoma (OS). The aim of this study was to investigate the functional significance and molecular of the let-7g in OS cells. The expression levels of let-7g was significantly down-regulated in OS cell lines U2-OS and HOS cell compared to osteoblast cell lines HOB cell. Moreover, bioinformatic prediction suggested that Aurora-B, which is overexpressed and functions as an oncogene in OS cells, is a putative target gene of let-7g. Using mRNA and protein expression analysis and luciferase assays, we further identified let-7g directly regulated Aurora-B expression in OS cells. Functional investigation revealed both restoration of let-7g and silencing Aurora-B induce cell apoptosis and suppressed cell viability, migratory and invasive ability in OS cells. Finally, we found that silencing Aurora-B in OS cells could partly dampen anti-let-7g mediated tumor promotion. Thus, our findings suggested that let-7g inhibits OS cell malignant phenotype at least partly through targeting Aurora-B. Targeting of let-7g and Aurora-B may be a novel therapeutic strategy for treating OS.

**Keywords:** Osteosarcoma, let-7, Aurora-B, metastasis

**Introduction**

Osteosarcoma (OS) is the most common primary malignant tumor of bone occurred in young adolescent and children. This disease has a poor prognosis because of the metastases in the period of tumor progression, which are usually developed previous to the clinical diagnosis. Clearly, the impact of identifying factors that govern proliferation and metastasis is essential in the management of osteosarcoma.

Aurora-B is one of the major protein kinases that ensures the proper execution and fidelity of mitosis. Increasing evidences showed that up-regulated Aurora-B expression involved in growth, invasion and metastasis in various malignant tumors, which make it believed to be an important anti-tumor target [1, 2]. Li Y et al. showed that down-regulation of Aurora-B could inhibit proliferation and metastasis, induce G2/M phase arrest in clear cell renal cell carcinoma cells and exert antitumor activity in an SN12C xenograft model [3]. Our previous studies revealed that Aurora-B was elevated expression in OS tissues and knockdown of Aurora-B suppressed OS cells proliferation, migratory and invasion in vitro [4]. However, the molecular mechanisms on overexpression of Aurora-B in OS are still uncertain.

Numerous studies showed that MicroRNAs (miRNAs) plays an important role in regulating expression of oncogenes. MiRNAs are a category of small non-coding RNA molecule approximately 22 nucleotides in length. Mature miRNAs are involved in the transcriptional and post-transcriptional regulation of gene expression, through binding to complementary sequences in the 3’ untranslated regions (3’ UTRs) of target mRNA transcripts [5]. Accumulating studies have demonstrated that miRNAs played critical role in cell proliferation, apoptosis and metastasis [6-9]. Let-7 cluster has been shown to be significantly correlated with the occurrence and development of cancer, suggesting it is involved in the regulation of oncogenic pathways in
Let-7g changes malignant phenotype of OS cells

<table>
<thead>
<tr>
<th>Position 93-99 of AURKB 3’ UTR</th>
<th>predicted consequential pairing of target region (top) and miRNA (bottom)</th>
<th>seed match</th>
<th>site-type contribution</th>
<th>3’ pairing contribution</th>
<th>local AU contribution</th>
<th>position contribution</th>
<th>TA contribution</th>
<th>SPS contribution</th>
<th>context+ score</th>
<th>context+ score percentile</th>
<th>conserved branch length</th>
<th>PCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-let-7c</td>
<td>6’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.012</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.026</td>
<td>-0.25</td>
<td>88</td>
<td>1.548</td>
<td>0.78</td>
</tr>
<tr>
<td>hsa-let-7a</td>
<td>3’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.012</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.025</td>
<td>-0.25</td>
<td>88</td>
<td>1.548</td>
<td>0.78</td>
</tr>
<tr>
<td>hsa-let-7d</td>
<td>5’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.012</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.025</td>
<td>-0.25</td>
<td>88</td>
<td>1.548</td>
<td>0.78</td>
</tr>
<tr>
<td>hsa-miR-98</td>
<td>3’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.012</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.025</td>
<td>-0.25</td>
<td>88</td>
<td>1.548</td>
<td>0.78</td>
</tr>
<tr>
<td>hsa-let-7f</td>
<td>5’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.012</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.026</td>
<td>-0.25</td>
<td>88</td>
<td>1.548</td>
<td>0.78</td>
</tr>
<tr>
<td>hsa-miR-445D</td>
<td>3’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.003</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.026</td>
<td>-0.25</td>
<td>88</td>
<td>1.548</td>
<td>0.78</td>
</tr>
<tr>
<td>hsa-let-7g</td>
<td>5’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.012</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.026</td>
<td>-0.25</td>
<td>88</td>
<td>1.548</td>
<td>0.78</td>
</tr>
<tr>
<td>hsa-let-7e</td>
<td>3’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.012</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.025</td>
<td>-0.25</td>
<td>88</td>
<td>1.548</td>
<td>0.78</td>
</tr>
<tr>
<td>hsa-let-7b</td>
<td>5’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.021</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.026</td>
<td>-0.24</td>
<td>87</td>
<td>1.548</td>
<td>0.78</td>
</tr>
<tr>
<td>hsa-let-7i</td>
<td>3’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.040</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.026</td>
<td>-0.23</td>
<td>85</td>
<td>1.548</td>
<td>0.78</td>
</tr>
<tr>
<td>hsa-miR-4500</td>
<td>5’ . . . . . . . . . . . . . . . . . . . . . . . 3’</td>
<td></td>
<td>-0.120</td>
<td>0.040</td>
<td>-0.053</td>
<td>-0.056</td>
<td>-0.010</td>
<td>-0.026</td>
<td>-0.23</td>
<td>85</td>
<td>1.548</td>
<td>0.78</td>
</tr>
</tbody>
</table>

Figure 1. Results of bioinformatic research about microRNAs targeting Aurora-B. There are 11 members of let-7 cluster may target Aurora-B at the position of 93-99 bp.
Let-7g changes malignant phenotype of OS cells

numerous types of tumors [10-13]. However, whether let-7 cluster involved in the development of osteosarcoma and the potential molecular mechanisms are remain unexplored.

In this study, we found that let-7g, one member of let-7 cluster, mediated Aurora-B overexpression and promoted cell proliferation, migration and invasion in OS cells.

Results

Aurora-B may be a target for let-7 cluster

To identify potential miRNAs that may regulate Aurora-B expression, the bioinformatic research analysis (Pictar, Targetscan) was performed. Result showed that Aurora-B is included in the conserved targets of let-7 cluster as shown in Figure 1. Furthermore, the 3'UTR of Aurora-B was cloned and subjected to a luciferase reporter assay in U2-OS cell along with let-7 cluster mimics. We found that 8 members of let-7 cluster (let-7a/b/c/d/e/f/g/i) can significantly inhibit the reporter activity of the Aurora-B 3'UTR (Figure 2). To Further explore whether let-7a/g/i/d/b/c/e regulates Aurora-B, its wild-type 3'UTR was mutated by deleting the 7-bp sequence (D-Mut) complementary to let-7a/g/i/d/b/c/e or by introducing point mutations (Point-Mut) (Figure 2). We found that the inhibitory effect of let-7a/b/c/d/e/f/g/i on AuroraB reporter activity was significantly restrained (Figure 2). It indicated that Aurora-B may be negatively targeted by let-7a/b/c/d/e/f/g/i in OS.

Let-7a/b/c/d/e/f/g/i were downregulated expression in OS cells versus osteoblast cells

Previously, let-7 cluster has been reported as a tumor suppressor in colon, breast, lung, endometrial and cancers [14, 15]. Whereas the correlation between let-7 cluster dysregulation and OS remains unknown. The expression level of let-7a/b/c/d/e/f/g/i in OS cell (U2-OS and HOS) and osteoblast cell (HOB cell) was measured by qRT-PCR. The results revealed that the expression of let-7a/b/c/d/e/f/g/i was significantly lower in OS cells than those in osteoblast cells, espesially let-7g (Figure 3). It suggested that the let-7 microRNA family may play an essential role in OS malignant phenotype. Let-7g was the most significantly changed let-7 miRNA. Thus, let-7g was chosen as the candidate miRNA to conduct functional investigation in OS.

Let-7g inhibit Aurora-B expression in OS cells

To determine whether Aurora-B was regulated by let-7g in OS, the OS cell lines U2-OS and HOS cells that overexpression Aurora-B were treated with let-7g mimic and anti-let-7g, respectively. The expression of Aurora-B was measured by western blot and qRT-PCR. The results showed that the expression levels of Aurora-B mRNA and protein were significant lower in cells treated with let-7g mimic than those cells treated with anti-let-7g inhibitor and untreated (Figure 4). It indicated that let-7g inhibit Aurora-B expression in OS cells.

Let-7g changes the malignant phenotype of OS cells by targeting Aurora-B

To explore the functional relationship between let-7g and Aurora-B in OS, the U2-OS and HOS cells were treated with let-7g mimic or anti-let-7g inhibitor and the ability of cells proliferation, migration and invasion was measured by MTT, wound healing and transwell invasion assays. It
Let-7g changes malignant phenotype of OS cells

was found that the cell proliferation, migratory and invasive ability in elevated let-7g cells was significantly reduced compared to lower let-7g cells (Figures 5-7), suggesting that let-7g has anti-malignant phenotype effects in OS cells.

Furthermore, to investigate whether let-7g inhibits OS cells malignant phenotype by targeting Aurora-B, the OS cells were infected with let-7g mimic, anti-let-7g inhibitor and LV-sh Aurora-B combined with anti-let-7g (co-infected), respectively. In western blot assays, the results revealed that the Aurora-B protein level was significantly inhibited in cells infected with let-7g mimic. However, partially down-regulated Aurora-B protein level in co-transfected cells was observed (Figures 5-7). The malignant phenotype of cell was investigated by measures the proliferation, migrator and invasive ability. The data showed the tumor promotion mediated by anti-let-7g was partly inhibited by silencing Aurora-B in OS cells (Figures 5-7). These data suggested that let-7g alters OS cells malignant phenotype at least partly by targeting Aurora-B in vitro.

Discussion

In this study, we firstly found that let-7g expression is decreased in OS cells and restoring let-7g expression inhibits cell proliferation, migration and invasion by targeting Aurora-B in vitro.

A larger number of evidences revealed that Aurora-B involved in malignant tumor cells growth and metastasis [16]. In our previous study, we found that Aurora-B was overexpressed in OS tissues and cells and inhibition of Aurora-B by shRNA and small molecular inhibitor could suppress U2-OS cell proliferation, migration and invasion. In this study, to explore the potential molecular mechanisms on up-regulated Aurora-B expression in OS, we performed the bioinformatic research analysis to identify potential miRNAs that may interact with Aurora-B. The results showed that 11 members of let-7 cluster may be target Aurora-B. Furthermore, the luciferase reporter assay was performed to clarify whether Aurora-B is a potential target. The data indicated that eight mature miRNAs of let-7 cluster, including let-7a/b/c/d/e/f/g/i, may negatively target Aurora-B gene in OS cell.

One member of let-7 cluster was the first identified human miRNA in 2000 by Reinhart [17]. Numerous members of the let-7 cluster have been identified in various species [18]. So far, 11 mature subtypes of the let-7 cluster have been found in humans, including let-7a, -7b, -7c, -7d, -7e, -7f, -7g, -7i, miR-98, miR-4500 and miR-4458. Increasing studies have reported that members of let-7 cluster are down-regulated in various types of cancer, including lung cancer, gastric tumors, colon cancer, nasopharyngeal carcinoma, endometrial carcinoma and Burkitt’s lymphoma [19-21]. Decreased expression levels of let-7 cluster have been associated with the clinical postoperative survival of patients with malignant tumor [22, 23]. The let-7 cluster is involved in the proliferation, apoptosis and metastasis of cancer cells [24]. Interestingly, the upregulated expression of let-7 cluster was also observed in head and neck squamous cell carcinoma [25]. In present study, we measured the expression levels of...
Let-7g changes malignant phenotype of OS cells

To further elucidate whether let-7g alters OS cells malignant phenotype via directly targeting Aurora-B in OS, the correlation between let-7g and the Aurora-B expression was measured using qRT-PCR in OS cell lines. The data revealed that let-7g negative regulates Aurora-B expression at the post-transcriptinal level. In addition, the functional relationship between let-7g and Aurora-B in OS cells was analyzed. The results showed that up-regulated let-7g inhibit cell viability, migratory and invasive ability, and the tumor promotion mediated by anti-let-7g inhibitor was partly inhibited by silencing Aurora-B. These data suggested that let-7g alters OS cells malignant phenotype at least partly by targeting Aurora-B in vitro.

In conclusion, we findings suggested that down-regulated expression of let-7 microRNA family member is closely related to OS and let-7g alters the malignant of OS cells by negative regulating Aurora-B expression. Let-7g and members of let-7 cluster (including let-7a, -7b, -7c, -7d, -7e, -7f, -7g, -7i) in OS cells lines (U2-OS and HOS cell) and osteoblast cells (HOB) by qRT-PCR. We found that those members of let-7 cluster were lower expression in OS cells compared to HOB cells and let-7g was the most significant dysregulated miRNAs. It suggested that those miRNAs may play an important role in regulating cellular processes in osteosarcoma.

Decreased expression of MicroRNAs promoted tumorigenesis in various malignant tumors [24]. In this study, of the most significantly dysregulated miRNAs, let-7g, was highlighted for further functional analysis to identify its role in OS. The OS cells were treated with let-7g mimic and anti-let-7g respectively and the cell malignant phenotype was evaluated by investigating the cell viability, migratory and invasive ability. We found that let-7g prevented OS cells proliferation, migration and invasion in vitro.

Figure 4. Let-7g inhibits Aurora-B expression in OS cells. Aurora-B mRNA (C, D) and protein (A, B) were significant lower in cells treated with let-7g mimic than those cells treated with anti-let-7g inhibitor and untreated. (Columns, mean (n=6); bars, S.D. *P < 0.05, ΔP < 0.05 VS NC, ▲P < 0.05 VS NC and anti-let-7g. NC, Negative control. anti-let-7g, anti-let-7g inhibitor (OS cells transfected by the reverse complementary sequence of let-7g). Co-infected, OS cells transfected by LV-shAurora-B combined with anti-let-7g. Let-7g, OS cells transfected by let-7g mimics).
Let-7g changes malignant phenotype of OS cells

Aurora-B corporately provide novel diagnostic biomarkers for OS, and targeting of let-7g and Aurora-B may aid in the development of novel therapeutic strategy for OS management. However, the tumor microenvironment played a key role in tumor development, progression and metastasis, therefore, further experiments in vivo are required to elucidate the potential of let-7g and Aurora-B as a target for the treatment of OS metastasis and a predictor of prognosis.

Materials and methods

Bioinformatic prediction

To predict miRNA targeting potentially at Aurora-B, we used the following bioinformatic algorithms: PicTar [26], TargetScan6.2 [27].

 Luciferase reporter assay

Primers were designed in accordance with the human Aurora-B (AURKB) gene (NM_004217.3) sequences. And a fragment of the 3'-UTR of AURKB was amplified from U2-OS cells by PCR using the forward primer 5'-CCCCTCAGATGGTCCCTGCTATTCACT-3' and the reverse primer 5'-CTCGGAGCCGCTGAGTACAAAGCTTCAGCCTT-3'. Following digestion of the PCR product by Xhol and NotI, the AURKB 3'-UTR was cloned into pSiCHECK2 (Promega, Madison, WI, USA) at the XhoI and NotI sites. All PCR products were verified by DNA sequencing. U2-OS cells were co-transfected with the pSiCHECK2 vectors containing the 3'-UTR of AURKB (or variants) and let-7 or the negative control miRNA. Luciferase activity was measured 48 h after transfection. The firefly luciferase activity was then normalized to the Renilla luciferase activity.

Cell culture

The human OS cell line, U2-OS and HOS, and HOB was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA), and cells were routinely cultured in DMEM medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma, St. Louis, MO, USA) in a humidified 37°C incubator containing 5% CO₂.

qRT-PCR

The total RNA was isolated from cells with Trizol reagent (Invitrogen, USA). Reverse transcription was performed with 2 mg of total RNA using PrimeScript Rtreagent Kit (Takara, Co, Japan). Then each sample was analyzed by quantitative real-time PCR (qPCR) (Bio-Rad, Hercules, CA, USA) under the conditions described in the SYBR Premix Ex Tap II (Invitrogen, USA): 50°C for 2 min, 95°C for 2 min, followed by 40 cycles of 95°C for 15 s, 60°C for 30 s. Primer sequenc- es information was in summary as Table 1. Relative expression was calculated using the 2^ΔΔCt method. All experiments were repeated by six times over multiple days.

Transfection

The miRNA mimics for let-7g (hsa-let-7g, 5'-UGAGGUAGUAGUU GUACAGUU-3'), and the
**Figure 6.** The migratory ability of OS cells was measured by wound healing assays. The migratory rate was significantly lower in cells infected with let-7g mimics than Let-7g changes malignant phenotype of OS cells infected with negative mimics, suggesting that enhanced expression of let-7g could inhibit OS cells migration in vitro. The tumor migratory promotion mediated by anti-let-7g was partly inhibited by silencing Aurora-B in OS cells. (Columns, mean (n=6); bars, S.D. *P < 0.05, ΔP < 0.05 VS NC, ▲P < 0.05 VS NC and anti-let-7g.).

miRNA inhibitors for let-7g (The reverse complementary sequence of let-7g, 5'-AACGUACAAACUAUCACCUA-3'), and miRNA negative control (NC) were obtained from GenePharma (Shuzhou). U2-OS or HOS cells were transfected with 10 nM of tested miRNA mimics or inhibitors using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's
Let-7g changes malignant phenotype of OS cells

protocol. OS cells were infected with Lentivirus-Vectors of down-regulating Aurora-B (LV-Aurora-B) and negative Lentivirus-Vectors (LV-Neg) at MOI of 12.5 (U2-OS) or 25 (HOS). After 48 h transfection, cells were harvested for appropriate subsequent assays.

Western blot

Total protein from cells was extracted using RIPA lysis buffer containing 60 μg/ml PMSF. Protein concentration was determined by Bradford assay. Western blot analysis was conducted using antibodies against Aurora-B (Abcam, UK) and β-actin (Santa Cruz). The immune complexes were detected with proligh HRP Kit (pierce). The determination of the grayscale value was processed using ImageJ software. All experiments were repeated six times over multiple days.

Cell proliferation assay

Cells were cultured in 96-well tissue culture plates at a cell density of 5000 cells per well in culture medium. 3- (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide (MTT) assays were carried out at 490 nm wave length. All experiments were repeated six times over multiple days.

Transwell invasion assays

Cell invasion was measured in 24-well plates by Transwell assay using a chamber containing the polyethylene terephthalate filter membrane with 8-μm pores (BD Biosciences) according to the manufacturer's protocol. The medium in the lower chamber contained 5% fetal calf serum as a source of chemoattractants. Cells were suspended in serum-free medium and
Let-7g changes malignant phenotype of OS cells

Cells that passed through the Matrigel-coated membrane were stained with Diff-Quik (Sysmex, Kobe, Japan) and photographed (×400). Photographs were taken at 24 h, and cell counting was measured by Image J (NCBI). The values for invasion were obtained by counting three fields per membrane and represented as the average of six independent experiments done over multiple days.

Wound healing assays

Cell migration was assessed by determining the ability of the cells to move into a cellular space in a two-dimensional in vitro 'wound healing assay'. In brief, the cells were grown to confluence in 6-well tissue culture plastic dishes to a density of 5×10^6 cells/well. The cells were denuded by dragging a rubber policeman (Fisher Scientific, Hampton, NH, USA) through the center of the plate. The cultures were rinsed with PBS and replaced with fresh DMEM alone or containing 10% FBS, following which the cells were incubated at 37°C for 24 h. Images were captured at 0 and 24 h and the migrated distance was measured using ImageJ software (NIH, Bethesda, MD, USA). All experiments were repeated six times over multiple days.

Statistical analysis

Statistical comparisons were performed using SPSS software version 13.0 (SPSS Inc, Chicago, IL, USA). All measurement data are presented as the mean±SD, and the one-way ANOVA with a post-hoc test (Student-Newman-Keuls test) was performed for statistical analysis. A P-value < 0.05 was considered to indicate a statistically significant difference.

Acknowledgements

The present study was supported by grants from the National Natural Science Foundation of China (No. 81260400), the National Science Foundation of Jiangxi Province (No. 20114-BAB205093) and Jiangxi Province Education Department of Science and Technology (No. GJJ12097, GJJ11316).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Zhi Li Liu or Dr. Zhi Hong Zhang, Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Yong Wai Zheng Street 17, Nanchang 330006, Jiangxi, P. R. China. E-mail: zgm7977@163.com (ZLL); 1380305665@163.com (ZHZ)

References


Let-7g changes malignant phenotype of OS cells


